AGNPF (Algernon Pharmaceuticals) Interest Expense : $0.00 Mil (TTM As of Nov. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Algernon Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Algernon Pharmaceuticals's interest expense for the three months ended in Nov. 2024 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Nov. 2024 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Algernon Pharmaceuticals's Operating Income for the three months ended in Nov. 2024 was $ -0.27 Mil. Algernon Pharmaceuticals's Interest Expense for the three months ended in Nov. 2024 was $ 0.00 Mil. Algernon Pharmaceuticals has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Algernon Pharmaceuticals Interest Expense Historical Data

The historical data trend for Algernon Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algernon Pharmaceuticals Interest Expense Chart

Algernon Pharmaceuticals Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Aug24

Interest Expense

Get a 7-Day Free Trial

Algernon Pharmaceuticals Quarterly Data
	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Algernon Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Nov. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Algernon Pharmaceuticals (OTCPK:AGNPF) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Algernon Pharmaceuticals's Interest Expense for the three months ended in Nov. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Nov. 2024 was $-0.27 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Nov. 2024 was $0.00 Mil.

Algernon Pharmaceuticals's Interest Coverage for the quarter that ended in Nov. 2024 is calculated as

Algernon Pharmaceuticals had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Algernon Pharmaceuticals Inc has no debt.

Algernon Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algernon Pharmaceuticals Inc (OTCPK:AGNPF) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

AGW0:Germany AGN:Canada

Address

601 West Broadway, Suite 400, Vancouver, BC, CAN, V5Z 4C2

Website

https://www.algernonpharmaceuticals.com

Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis, and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.